Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
SARS (Severe Acute Respiratory Syndrome): full-pipeline trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
SARS (Severe Acute Respiratory Syndrome): 4 US clinical trials tracked, none currently recruiting.
SARS (Severe Acute Respiratory Syndrome) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Lucira Health, running 1 of these trials.
Enrollment posture brief
Registry condition sars-severe-acute-respiratory-syndrome
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
SARS (Severe Acute Respiratory Syndrome) has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for SARS (Severe Acute Respiratory Syndrome) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
SARS (Severe Acute Respiratory Syndrome) is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
University of Minnesota
NCT04546581
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
Massachusetts General Hospital
NCT04306393
Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)
University of Washington
NCT05074719
A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion
Lucira Health
NCT04720794
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on SARS (Severe Acute Respiratory Syndrome) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on SARS (Severe Acute Respiratory Syndrome) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this SARS (Severe Acute Respiratory Syndrome) page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No SARS (Severe Acute Respiratory Syndrome) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lucira Health sponsors the most SARS (Severe Acute Respiratory Syndrome) trials on record, review their full trial history before evaluating a specific study. See Lucira Health's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This SARS (Severe Acute Respiratory Syndrome) condition card totals 4 registered trials; most-linked intervention Lucira COVID-19 All-In-One test kit; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.